Rajwa Pawel, Syed Jamil, Leapman Michael S
Department of Urology, Medical University of Silesia, 41-800, Zabrze, Poland.
Department of Urology, Yale University School of Medicine, 310 Cedar Street BML 238c, PO Box 208058, New Haven, CT, 06520, USA.
Abdom Radiol (NY). 2020 Dec;45(12):4031-4039. doi: 10.1007/s00261-020-02496-5.
To review the current body of evidence surrounding non-imaging biomarkers in patients with known or suspected prostate cancer.
Several non-imaging biomarkers have been developed and are available that aim to improve risk estimates at several clinical junctures. For patients with suspicion of prostate cancer who are considering first-time or repeat biopsy, blood- and urine-based assays can improve the prediction of harboring clinically significant disease and may reduce unnecessary biopsy. Blood- and urine-based biomarkers have been evaluated in association with prostate MRI, offering insights that might augment decision-making in the pre and post-MRI setting. Tissue-based genomic and proteomic assays have also been developed that provide independent assessments of prostate cancer aggressiveness that can complement imaging.
A growing number of non-imaging biomarkers are available to assist in clinical decision-making for men with known or suspected prostate cancer. An appreciation for the intersection of imaging and biomarkers may improve clinical care and resource utilization for men with prostate cancer.
回顾目前围绕已知或疑似前列腺癌患者非影像学生物标志物的证据。
已经开发并可获得几种非影像学生物标志物，旨在在几个临床阶段改善风险评估。对于怀疑患有前列腺癌且正在考虑首次或重复活检的患者，基于血液和尿液的检测可以改善对患有临床显著疾病的预测，并可能减少不必要的活检。基于血液和尿液的生物标志物已与前列腺MRI联合进行评估，提供了可能增强MRI前后决策的见解。基于组织的基因组和蛋白质组检测也已开发出来，可提供对前列腺癌侵袭性的独立评估，以补充影像学检查。
越来越多的非影像学生物标志物可用于协助已知或疑似前列腺癌男性患者的临床决策。了解影像学和生物标志物的交叉点可能会改善前列腺癌男性患者的临床护理和资源利用。
